Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $56.50 Consensus Target Price from Analysts
Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target […]
Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price target […]
